Siltuximab
22-512
Phase 2 small_molecule active
Quick answer
Siltuximab for Schwannomatosis is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Schwannomatosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active